Compare
Agenus Inc vs ImmunityBio, Inc. vs REGENXBIO Inc. vs Autolus Therapeutics plc
| Latest fiscal year | Agenus Inc AGEN | ImmunityBio, Inc. IBRX | REGENXBIO Inc. RGNX | Autolus Therapeutics plc AUTL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $114.20M | $113.29M | $170.44M | $75.39M |
| Revenue growth (YoY) | +10.4% | +668.3% | +104.5% | +644.9% |
| Gross margin | n/a | n/a | n/a | -27.8% (computed) |
| Operating margin | -17.7% | -226.0% | -94.6% | -358.9% |
| Net margin | -2.7% | -310.2% | -113.8% | -381.4% |
| Net income | -$3.08M | -$351.40M | -$193.88M | -$287.53M |
| EPS (Diluted) | $0.00 | -$0.38 | -$3.76 | -$1.08 |
| Operating cash flow | -$77.19M | -$304.94M | -$123.96M | -$283.57M |
| Free cash flow | -$77.20M | -$308.78M | -$126.38M | -$302.61M |
| Cash & equivalents | $3.00M | $88.33M | $34.47M | $104.13M |
| Total assets | $226.80M | $501.90M | $453.03M | $589.07M |
| Total liabilities | n/a | $1.00B | $350.30M | $410.94M |
| Shareholders' equity | -$271.11M | -$500.47M | $102.73M | $178.13M |
| Return on year-end equity | n/a | n/a | -188.7% | -161.4% |
| Shares outstanding | 35.32M | 1.01B | 50.89M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Agenus Inc | ImmunityBio, Inc. | REGENXBIO Inc. | Autolus Therapeutics plc |
|---|---|---|---|---|
| Latest | $114.20M Ended 2025-12-31 | $113.29M Ended 2025-12-31 | $170.44M Ended 2025-12-31 | $75.39M Ended 2025-12-31 |
| 1 year earlier | $103.46M Ended 2024-12-31 | $14.74M Ended 2024-12-31 | $83.33M Ended 2024-12-31 | $10.12M Ended 2024-12-31 |
| 2 years earlier | $156.31M Ended 2023-12-31 | $622.0K Ended 2023-12-31 | $90.24M Ended 2023-12-31 | $1.70M Ended 2023-12-31 |
| 3 years earlier | $98.02M Ended 2022-12-31 | $240.0K Ended 2022-12-31 | $112.72M Ended 2022-12-31 | n/a |
| 4 years earlier | $295.67M Ended 2021-12-31 | $934.0K Ended 2021-12-31 | $470.35M Ended 2021-12-31 | n/a |